Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 10;9(2):54.
doi: 10.3390/jcdd9020054.

What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies

Hisham A Badreldin  1 , Nasser Aldosari  1 , Lama Alnashwan  1 , Taif Almutairi  1 , Nada Yousif  1 , Khalid Alsulaiman  1 , Ohoud Aljuhani  2 , Awatif Hafiz  2 , Omar Alshaya  1
Affiliations
Review

What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies

Hisham A Badreldin et al. J Cardiovasc Dev Dis. .

Abstract

Early research on neprilysin inhibition showed that sacubitril/valsartan, a combination of the valsartan and the neprilysin inhibitor sacubitril, was superior to enalapril in patients with heart failure with reduced ejection fraction (HFrEF) in the PARADIGM-HF study in 2014. Therefore, for patients with HFrEF, worldwide recommendations have been reformed to include sacubitril/valsartan. In addition, sacubitril/valsartan has been investigated in other cardiovascular disease states, such as patients with heart failure and preserved ejection fraction (HFpEF) and following myocardial infarction (MI) events. In February 2021, the FDA expanded the indication use of sacubitril/valsartan to include the HFpEF patient population based on the results of the PARAGON-HF trial. However, randomized clinical trials post-MI did not show promising results. Sacubitril/valsartan is currently being investigated in many other cardiovascular and non-cardiovascular conditions. This review aims to shed light and summarize the ongoing sacubitril/valsartan registered studies on the United States National Library of Medicine clinical trials registry.

Keywords: cardiovascular disease; sacubitril; valsartan.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Infographic of the major ongoing sacubitril/valsartan registered studies on ClinicalTrials.gov (accessed on 3 January 2022).
See this image and copyright information in PMC

References

    1. Kaplinsky E. Sacubitril/valsartan in heart failure: Latest evidence and place in therapy. Ther. Adv. Chronic Dis. 2016;7:278–290. doi: 10.1177/2040622316665350. - DOI - PMC - PubMed
    1. Mcmurray J.J.V., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., Rouleau J.L., Shi V.C., Solomon S.D., Swedberg K., et al. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. N. Engl. J. Med. 2014;371:993–1004. doi: 10.1056/NEJMoa1409077. - DOI - PubMed
    1. Velazquez E.J., Morrow D., Devore A.D., Duffy C.I., Ambrosy A.P., McCague K., Rocha R., Braunwald E. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure. N. Engl. J. Med. 2019;380:539–548. doi: 10.1056/NEJMoa1812851. - DOI - PubMed
    1. Solomon S.D., McMurray J.J., Anand I.S., Bayes-Genis A., Lam C.S., Maggioni A.P., Martinez F., Packer M., Pfeffer M.A., Pieske B., et al. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N. Engl. J. Med. 2019;381:1609–1620. doi: 10.1056/NEJMoa1908655. - DOI - PubMed
    1. Pfeffer M.A., Claggett B., Lewis E.F., Granger C.B., Køber L., Maggioni A.P., Mann D.L., McMurray J.J., Rouleau J.-L., Solomon S.D., et al. Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction. N. Engl. J. Med. 2021;385:1845–1855. doi: 10.1056/NEJMoa2104508. - DOI - PubMed